These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32447348)

  • 21. Comparison of three mobilization protocols for peripheral blood stem cell apheresis with Spectra Optia continuous mononuclear cell protocol in healthy dogs.
    Kim S; Hosoya K; Kobayashi A; Okumura M
    Vet Comp Oncol; 2019 Mar; 17(1):61-68. PubMed ID: 30221450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
    Varmavuo V; Silvennoinen R; Anttila P; Säily M; Sankelo M; Putkonen M; Ahonen J; Mahlamäki E; Mäntymaa P; Savolainen ER; Remes K; Jantunen E
    Ann Hematol; 2016 Oct; 95(10):1653-9. PubMed ID: 27485453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Plerixafor Use at Different Peripheral Blood CD34
    Shah EE; Young RP; Wong SW; Damon LE; Wolf JL; Shah ND; Leavitt AD; Loeffler P; Martin TG
    Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
    Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
    Tichopád A; Vítová V; Kořístek Z; Lysák D
    J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
    Gutiérrez-Aguirre CH; Alvarado-Navarro DM; Palomares-Leal A; Mejía-Jaramillo G; Salazar-Riojas R; León AG; Colunga-Pedraza PR; Sotomayor-Duque G; Jaime-Pérez JC; Cantú-Rodríguez OG; Del Carmen Tarín-Arzaga L; Flores-Jiménez JA; Gómez-Almaguer D
    Transfusion; 2019 Dec; 59(12):3721-3726. PubMed ID: 31618456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
    Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ; Maziarz RT; Bensinger WI; Nademanee A; Liesveld J; Badel K; Dehner C; Gibney C; Bridger G; Calandra G
    Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.
    Maechler M; Bacher U; Daskalakis M; Nilius H; Nagler M; Taleghani BM; Jeker B; Pabst T
    Hematol Oncol; 2023 Aug; 41(3):583-586. PubMed ID: 35920140
    [No Abstract]   [Full Text] [Related]  

  • 33. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
    Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
    Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.
    Chua CC; Lim HY; Chai KL; Ong J; Sim S; Wood C; Dickinson M; Campbell P; Hempton J; King H; Dowsing C; Bergin K; Muir S; Gibbs S; Grigg A
    Bone Marrow Transplant; 2018 Sep; 53(9):1116-1123. PubMed ID: 29523889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of plerixafor in autologous peripheral blood stem cell collection].
    Yogo T; Tsukada N; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Okazuka K; Ishida T; Suzuki K
    Rinsho Ketsueki; 2019; 60(3):165-170. PubMed ID: 31068511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.
    Park G; Shayani S; Stiller T; Wang S; Yuan S
    Transfusion; 2018 Feb; 58(2):323-329. PubMed ID: 29134662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
    Bakeer M; Zubair AC; Roy V
    Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
    Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S; Waller EK
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1393-5. PubMed ID: 23764455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of mobilization efficacy with an extended interval following plerixafor administration.
    Stump SE; Trepte M; Shaw JR; Grgic T; Ptachcinski JR; Sharf A; Riches M; Shea TC; Park YA; Alexander MD
    J Oncol Pharm Pract; 2020 Oct; 26(7):1590-1597. PubMed ID: 32063103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.